Company Overview of Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc., a clinical-stage specialty pharmaceutical company, focuses on identifying, developing, and commercializing topical drugs to address various unmet needs in dermatology. Its lead drug candidate is A-101, a hydrogen peroxide topical solution that has completed three Phase II clinical trials for the treatment of seborrheic keratosis (SK), a common non-malignant skin tumor. The company is also developing A-101 as a prescription treatment for common warts; and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts. Aclaris Therapeutics, Inc. was founded in 2012 and is headquartered in Malvern, Pennsylvania.
101 Lindenwood Drive
Malvern, PA 19355
Founded in 2012
Key Executives for Aclaris Therapeutics, Inc.
Chief Executive Officer, President and Director
Chief Financial Officer and Secretary
Chief Legal Officer and Assistant Secretary
Vice President of Clinical Operations
Compensation as of Fiscal Year 2015.
Aclaris Therapeutics, Inc. Key Developments
Aclaris Therapeutics Seeks Acquisitions
Aug 18 15
Aclaris Therapeutics, Inc. intends to use the net proceeds from IPO to acquire additional drug candidates.
Aclaris Therapeutics, Inc. Announces Statistically Significant Results from Phase 2 Clinical Trial of Its Lead Drug Candidate, A-101
Mar 17 15
Aclaris Therapeutics, Inc. announced statistically significant results from a Phase 2 clinical trial of its lead drug candidate, A-101. In the trial, A-101 demonstrated clinically and statistically significant improvements in removing seborrheic keratosis (SK) lesions on the face. SK is one of the most common types of skin tumors. Although the lesions are benign, many patients elect to have SK treated, either because the lesions have become irritated or because the patient feels they are cosmetically concerning. The double-blind, vehicle-controlled Phase 2 clinical trial was designed to evaluate the safety, tolerability and effectiveness of A-101 in removing targeted SK lesions on the face. The trial used a parallel-group design to compare two concentrations of A-101 and vehicle (placebo) in 120 subjects with SK lesions on the face. Results from the trial showed A-101 achieved statistical significance in clearing SK lesions in a dose-related fashion. A-101 was well tolerated at both concentrations studied. SK are among the most common skin tumors seen in middle-aged and older adults, affecting over 83 million people in the United States.i SK lesions have a waxy, scaly, slightly elevated appearance and often multiple growths are present. Currently, SK lesions are treated using modalities such as cryosurgery, electrosurgery, curettage, or surgical removal which may be painful and may often result in pigmentary changes and/or scarring at the treatment site.
Aclaris Therapeutics, Inc. Presents at Leerink's Global Healthcare Conference, Feb-12-2015 01:00 PM
Jan 30 15
Aclaris Therapeutics, Inc. Presents at Leerink's Global Healthcare Conference, Feb-12-2015 01:00 PM. Venue: Waldorf Astoria New York, New York, New York, United States. Speakers: Neal Walker, Chief Executive Officer, President and Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
August 28, 2015